LinkedIn
WebsiteIntroduction
APTEVO Therapeutics Inc (NASDAQ: APVO) is a clinical-stage biotechnology company headquartered in Seattle, Washington. Founded in 2016, Aptevo utilizes its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms to engineer monospecific, bispecific, and trispecific immunotherapies aimed at addressing hematologic and solid tumor malignancies.
| Ticker | Exchange | Price (USD) | % Change | Volume |
|---|---|---|---|---|
| APVO | NASDAQ | 2.4491 | +70.08% | 13,755,071 |
Corporate Structure
Aptevo employs approximately 51–200 people. Its executive leadership includes:
- Marvin L. White, President and CEO since August 2016, previously held roles at Eli Lilly and General Motors.
- Jeff Lamothe, EVP & COO, has overseen R&D, manufacturing, and operations since 2014 and has prior experience from Emergent BioSolutions and Cangene Corporation.
- Daphne Taylor, SVP & CFO, possesses 25 years of finance experience in the life sciences sector, including positions at BioLife Solutions and Cardiac Science.
- Dirk Huebner, M.D., CMO, has nearly three decades of clinical development experience from Boston Biomedical, Millennium/Takeda Oncology, and Genzyme.
Biotechnology by Sangharsh Lohakare
Recent Developments and News
- On August 14, 2025, L1 Capital Global Opportunities Master Fund, Ltd. filed a Schedule 13G/A reporting a 4.99% stake in Aptevo. CVI Investments, Inc. and Heights Capital Management, Inc. amended their Schedule 13G/A on the same date, reporting a combined ownership of 9.9%.
- On September 4, 2025, the company filed an 8-K (Items 8.01 and 9.01), providing updates on corporate governance and material events.
- In January 2025, Aptevo’s Senior Director of Protein Engineering, Peter Pavlik, Ph.D., chaired and presented at the Cambridge Healthcare Institute’s PepTalk conference on modular multispecific biologics utilizing the ADAPTIR platform.
- On September 13, 2025, Jeff Lamothe appeared on Bloomberg TV’s Small Stocks Big Money to discuss mipletamig’s clinical performance and the expansion of Aptevo’s CD3-derived portfolio.
- In September 2025, the company reported that the first patient treated in its RAINIER Phase 1b/2 trial of mipletamig achieved a 90% reduction in leukemic blasts within 30 days of treatment.
Financial and Strategic Analysis
Aptevo's stock price increased by 70.08% on September 16, 2025, indicating heightened investor interest in its clinical pipeline. The company remains pre-revenue, with research and development expenses as its primary outlay. Its lead candidate, mipletamig (CD3 × CD123 bispecific antibody), is currently in Phase 1b/2 for acute myelogenous leukemia, while ALG.APV-527 and APVO603 are progressing through Phase 1 and preclinical stages for various solid tumors. Collaboration agreements, such as the option deal with Alligator Bioscience AB for ALG.APV-527, provide non-dilutive funding and strategic partnerships. Monitoring of Aptevo’s cash position and burn rate will be crucial, especially ahead of the projected earnings release on November 5, 2025.
Market Position and Industry Context
The global bispecific antibody market is projected to grow by 44% through 2030, driven by advancements in engaging multiple immune pathways with improved safety profiles. Aptevo’s ADAPTIR platforms facilitate rapid design of multispecific molecules, situating the company within a competitive market that includes established biotechnology and pharmaceutical firms. The company's stock has exhibited volatility, evidenced by a 52-week trading range of $1.40 to $381.10, highlighting both potential growth and risks associated with clinical-stage oncology developers.
tl;dr
On September 16, 2025, APTEVO’s shares increased by 70% to $2.45 with a trading volume of 13.8 million shares. In September, the first patient in the RAINIER Phase 1b/2 trial achieved a 90% reduction in leukemic blasts. Leadership updates were reported through a Form 8-K on September 4, and two Schedule 13G/A amendments on August 14 revealed nearly 15% combined insider ownership. EVP & COO Jeff Lamothe and President & CEO Marvin White discussed pipeline progress on Bloomberg TV on September 13. The next quarterly results are expected on November 5, 2025.
